Enabling Digital Transformation for Life Sciences

Kneat develops and markets the next generation Kneat Gx software platform.  Kneat Gx, enables an end-to-end paperless process for all Validations, Commissioning and Qualification, Production Execution and Quality Document Management.  It allows users to electronically create, approve and execute all records, manage any exceptions and post approve the final executed records and reports in a controlled FDA 21 CFR Part 11 / EudraLex Annex 11 paperless compliant system.  Users with correct permissions can collaborate and see everything in real time on any device.  Kneat Gx helps Life Sciences to comply with the requirements of all global regulatory bodies such as the FDA, EMA, MHRA, ICH, WHO etc

Our customers are reporting greater data integrity, productivity improvements in excess of 100%, 50% reduction in cycle times and an overall higher compliance standard.

Click here to read some of their results

 

Press Releases

Published Case Study: Kneat enables Validation Process Innovation at pioneering Molecular Diagnostics Company
HALIFAX, Aug. 30, 2017 /CNW/ – kneat.com, inc. (TSXV: KSI) (“Kneat” or the “Company”), is pleased to announce that the case study entitled “Validation Process Innovation in Molecular Diagnostics” was published today in the Journal of Validation Technology.

This case study highlights substantial productivity and compliance improvements that a leading and pioneering molecular diagnostics customer gained by transitioning their overall validation process from paper-based to a compliant, fully electronic system which was made possible by Kneat’s software. In addition, it demonstrates Kneat’s ability to scale into other sectors within the life sciences industry; in this case laboratory and diagnostics.

Key results of the implementation of this electronic validation system are outlined in the case study and include:

· an end-to-end electronic computer system validation process;

· a streamlined process with embedded lean methodologies;

· a truly scalable, best practice validation framework;

· increased effectiveness at meeting the heightened compliance, efficiency and schedule demands on the business;

· real-time visibility on the validation status of any system via the management dashboard;

· instant central access to all current information on all validation activities and deliverables via web browser access on any device;

· productivity and cycle time improvements; and

· an electronic system with the same look and feel as a traditional, paper-based validation system.

“Our customers continue to endorse and scale Kneat’s next generation technology to multiple processes and sites. This is made possible because their users find it easy to install and use,” stated Eddie Ryan, Chief Executive Officer of Kneat. “Using Kneat has proven to reduce data integrity issues, increase productivity and deliver a higher compliance standard.”

About Kneat

Kneat, headquartered in Limerick, Ireland, develops and markets the next generation Kneat Gx software platform. Kneat Gx, enables an end-to-end paperless process for all validations, commissioning and qualification, production execution and quality document management. Kneat Gx allows users to electronically create, approve and execute all deliverables, manage any exceptions and post approve final deliverables in a controlled FDA Part 11/ Eudralex Annex 11 compliant platform. Users with correct permissions can see everything in real time. Customer case studies are reporting productivity improvements in excess of 100% and a higher compliance standard. www.kneat.com

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the ability to generate sales of the Kneat Gx platform, the ability to build relationships with current and prospective customers, the market potential for the Kneat Gx platform, the ability to develop new features for the Kneat Gx platform, and the compliance of the Kneat Gx platform under regulatory audit and inspection. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor’s own risk.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sarah Oliver, CFO, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: inquiry@kneat.com

Kneat.com,inc. announces the passing of director James Osborne
HALIFAX, Aug. 21, 2017 /CNW/ – kneat.com, inc. (TSXV: KSI) (“Kneat” or the “Company”), sadly announces that Mr. James Osborne, a director of the Company, recently passed away. Mr. Osborne has been a key member of the Kneat team and played an instrumental role in the transaction resulting in the public listing of Kneat Solutions Limited in 2016. Mr. Osborne was a well-respected board member of several companies including Ryanair and Eason, a former managing partner at one of the top legal firms in Ireland, A&L Goodbody, where he practised law for many years and a trusted business advisor to countless companies and colleagues within Ireland and abroad. “Kneat’s board of directors and management team is deeply saddened by the news of James’ passing and expresses its sincere condolences to his family. We will dearly miss James as he has been an avid supporter, mentor and friend to Kneat,” said Eddie Ryan, Chief Executive Officer of Kneat.

About Kneat

Kneat, headquartered in Limerick, Ireland, develops and markets the next generation Kneat Gx software platform. Kneat Gx, enables an end-to-end paperless process for all validations, commissioning and qualification, production execution and quality document management. Kneat Gx allows users to electronically create, approve and execute all deliverables, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11 compliant platform. Users with correct permissions can see everything in real time. Customer case studies are reporting productivity improvements in excess of 100% and a higher compliance standard. www.kneat.com.

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the ability to generate sales of the Kneat Gx platform, the ability to build relationships with current and prospective customers, the market potential for the Kneat Gx platform, the ability to develop new features for the Kneat Gx platform, and the compliance of the Kneat Gx platform under regulatory audit and inspection. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor’s own risk. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE Kneat.com For further information: Sarah Oliver, CFO, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: inquiry@kneat.com

Kneat.com, inc. provides a corporate update
HALIFAX, June 14, 2017 /CNW/ – kneat.com, inc. (TSXV: KSI) (“Kneat” or the “Company“), developer of the next generation Kneat Gx platform for regulated industries, is pleased to provide a corporate update outlining Kneat’s key accomplishments since completing a public listing on the Canadian TSX Venture Exchange on July 5, 2016.

“Since listing on the TSX Venture Exchange, Kneat has made significant advances, focusing on key milestones that will support Kneat’s long-term success,” said Eddie Ryan, Chief Executive Officer. “Firstly, we concentrated on building a strong, international sales team and the corporate infrastructure to support growth of the business and customer base.

Secondly, we continued to advance the Kneat Gx platform, including completion and deployment of our software as a service (“SaaS”) model. We can now address the needs of both segments of the market with on-premise or SaaS cloud deployments.

Most significantly, we achieved an industry breakthrough with global deployment of the Kneat Gx platform at a multi-national customer and published significant customer findings from the use of our platform by this customer. This success has increased market awareness of Kneat’s next generation capabilities within life sciences and other regulated industries.

Lastly, we secured additional funding to build on the momentum that we have gained from our achievements throughout 2016 and in the first half of 2017.”

Significant events included:

Signing of a $1.1 million contract and global deployment of the on-premise Kneat Gx platform at a multi-national customer site, replacing many of its paper-based validation and GxP testing processes within their highly regulated manufacturing facilities world wide Successful deployment and implementation of our SaaS platform at two customer sites. Kneat’s SaaS platform allows small to medium-size companies to benefit from paperless validation and GxP testing within their regulated facilities, without requiring a full in-house information technology infrastructure and support team The Journal of Validation Technology published the article ‘Case Study: Implementation of an Electronic Life Cycle Management System for Validation ….and Beyond‘ which outlines how the Kneat Gx platform assisted a multinational, highly regulated company implement best practices across its global network, providing productivity gains in excess of 100% and cycle time improvements of more than 50% in validation and GxP testing, with the prospect of leveraging the Kneat Gx platform across many other testing processes Hiring of two sales directors has added significantly to Kneat’s ability to market, demonstrate and sell to the European and North American markets Expansion of the Kneat development team has increased the pace of software development. This has allowed Kneat to substantially advance and move forward on the development road map and Closing of the $3 million private placement, as announced on May 31, 2017. The funds raised will be used to accelerate development, increase awareness of the Kneat Gx platform for multiple applications across several life sciences industries and enhance the team needed to support a growing list of customers.

About Kneat

Kneat, headquartered in Limerick, Ireland, develops and markets the next generation Kneat Gx software platform. Kneat Gx, enables an end-to-end paperless process for all validations, commissioning and qualification, production execution and quality document management. Kneat Gx allows users to electronically create, approve and execute all deliverables, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11 compliant platform. Users with correct permissions can see everything in real time. Customer case studies are reporting productivity improvements in excess of 100% and a higher compliance standard. www.kneat.com.

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the ability to generate sales of the Kneat Gx platform, the ability to build relationships with current and prospective customers, the market potential for the Kneat Gx platform, the ability to develop new features for the Kneat Gx platform, and the compliance of the Kneat Gx platform under regulatory audit and inspection. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor’s own risk. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE Kneat.com For further information: Sarah Oliver, CFO, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: inquiry@kneat.com

Kneat.com, inc. announces the closing of private placement
HALIFAX May 31, 2017 /CNW/ – kneat.com, inc. (TSkV: KSI) (“Kneat” or the “Company“), developer of the next generation Kneat Gx platform for regulated industries, today closed its previously announced non-brokered private placement for aggregate gross proceeds of $3,000,000 (the “Offering”). The Company issued 5,000,000 common shares at an issue price of $0.60 per share. The common shares issued in connection with the private placement are subject to a four-month hold period that will expire on October 1, 2017. Directors of the Company subscribed for an aggregate of 1,175,066 common shares. The proceeds of the Offering will be used to accelerate development of the on-premise and software as a service models of the Kneat Gx platform, increase the awareness of the platform for multiple applications across several life sciences industries and enhance the team needed to support a growing list of customers.

About Kneat

Kneat, headquartered in Limerick, Ireland, develops and markets the next generation Kneat Gx software platform. Kneat Gx, enables an end-to-end paperless process for all validations, commissioning and qualification, production execution and quality document management. Kneat Gx allows users to electronically create, approve and execute all deliverables, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11 compliant platform. Users with correct permissions can see everything in real time. Customer case studies are reporting productivity improvements in excess of 100% and a higher compliance standard. www.kneat.com.

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the ability to generate sales of the Kneat Gx platform, the ability to build relationships with current and prospective customers, the market potential for the Kneat Gx platform, the ability to develop new features for the Kneat Gx platform, and the compliance of the Kneat Gx platform under regulatory audit and inspection. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor’s own risk.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Kneat.com View original content: http://www.newswire.ca/en/releases/archive/May2017/31/c4815.html For further information: Sarah Oliver, CFO, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: inquiry@kneat.com

Kneat.com, inc. to complete non-brokered private placement
HALIFAX, May 10, 2017 /CNW/ – kneat.com, inc. (TSXV: KSI) (“Kneat” or the “Company“), the developer of the next generation Kneat Gx platform for regulated industries, is pleased to announce that it intends to complete a non-brokered private placement for an estimated aggregate gross proceeds of $3,000,000 (the “Offering”). The Company intends to issue an estimated 5,000,000 common shares at an issue price of $0.60 per share. The gross proceeds of the Offering will be used to accelerate development of the Kneat Gx platform, increase the awareness of the platform in several regulated industries and enhance the team needed to support a growing list of customers. “Our customers continue to see significant efficiencies and cost savings from the use of our platform. We intend to capitalize on this momentum with both our on-premise and SaaS models and further penetrate the life sciences industry.” said Eddie Ryan, Chief Executive Officer of Kneat. Closing of the Offering is subject to the approval of the TSX Venture Exchange. All securities issued pursuant to the Offering will be subject to a statutory four-month hold period in accordance with Canadian securities legislation.

About Kneat

Kneat, headquartered in Limerick, Ireland, develops and markets the next generation Kneat Gx software platform. Kneat Gx, enables an end-to-end paperless process for all validations, commissioning and qualification, production execution and quality document management. Kneat.Gx allows users to electronically create, approve and execute all deliverables, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11 compliant platform. Users with correct permissions can see everything in real time. Customer case studies are reporting productivity improvements in excess of 100% and a higher compliance standard. www.kneat.com.

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the ability to generate sales of the Kneat.Gx platform, the ability to build relationships with current and prospective customers, the market potential for the Kneat.Gx platform, the ability to develop new features for the Kneat.Gx platform, the ability of the Company to raise funds via a private placement, and the compliance of the Kneat.Gx platform under regulatory audit and inspection. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor’s own risk.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Kneat.com For further information: Sarah Oliver, CFO, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: inquiry@kneat.com

Kneat announces appointment of United States sales director
HALIFAX, April 3, 2017 /CNW/ – kneat.com, inc. (TSX-V: KSI) (“Kneat” or the “Company“) today announces the appointment of Mr. Derek Hughes in the role of United States Sales Director. Mr. Hughes will be responsible for sales of the Kneat.Gx software platform throughout the United States. Mr. Hughes joins the Kneat team after having spent the past six years successfully selling and promoting regulated software technologies into the life sciences industry throughout the United States. “The addition of Derek to our team will allow us to advance our sales strategy throughout North America”, said Eddie Ryan, Chief Executive Officer of Kneat. “The timing is right to ramp up our sales efforts in the United States in response to strong interest levels and a recent successful global deployment for one of our biotech customers who is achieving compelling compliance, productivity and time to market benefits.”

About Kneat

Kneat develops and markets the next generation Kneat Gx software platform. Kneat Gx is a systems lifecycle management solution which manages the full lifecycle from design through verification through ongoing change and final decommissioning. Our customers are streamlining all validations (process, equipment, computer, cleaning and laboratory), commissioning and qualification, product changeovers, vendor and project turnover management and more. For more information, please visit www.kneat.com.

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the ability to generate sales of the Kneat Gx platform, the ability to build relationships with current and prospective customers, the market potential for the Kneat Gx platform and the compliance of the Kneat Gx platform under regulatory audit and inspection. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor’s own risk.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE kneat.com

For further information:

Sarah Oliver, CFO, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: inquiry@kneat.com

Journal of Validation Technology publishes industry case study outlining efficiencies enabled by Kneat.Gx software
HALIFAX, Feb. 22, 2017 /CNW/ – kneat.com, inc. (TSX-V: KSI) (“kneat.com”, “Kneat”, or the “Company”) today announced that the Journal of Validation Technology published the article ‘Case Study: Implementation of an Electronic Life Cycle Management System for Validation ….and Beyond’ which outlines the value of the Kneat Gx software. The case study concludes that Kneat’s software assisted a multi-national biotech company to create best practices across its global network, providing productivity gains in excess of 100% and cycle time improvements of more than 50% in validation, with the prospect of leveraging the technology across many other testing processes. In addition to creating efficiencies, the Kneat Gx platform provides management with improved visibility and reporting abilities throughout the validation process, thus providing real-time results and control that are not possible using a paper-based system. “This case study further supports the time saving, efficiency and scalability that is possible when the Kneat Gx software is deployed,” stated Eddie Ryan, Chief Executive Officer of Kneat. “We look forward to providing further benefits to our customers as Kneat Gx expands into other processes.”

About Kneat

Kneat develops and markets the leading edge Kneat Gx software platform. Kneat Gx is an e-validation tool which enables the life sciences industry to become fully electronic with their many validation and testing processes. A key feature of the tool is that it does not restrict the user to a specific process, rather the user can quickly configure their process in the system. Our customers are streamlining all validations (process, equipment, computer, cleaning and laboratory), commissioning and qualification, product changeovers, vendor and project turnover management and more. For more information, please visit www.kneat.com.

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the relationship between Kneat and its customers, the use of Kneat within the customers’ manufacturing processes, the ability to scale the use of Kneat within its customers and the compliance of the Kneat Gx platform under regulatory audit and inspection. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investors’ own risk.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE kneat.com For further information: Sarah Oliver, CFO, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: inquiry@kneat.com

Multi-National Pharmaceutical Company Deploys Kneat’s E-Validation Platform Across All Sites
HALIFAX, Jan. 4, 2017 /CNW/ – kneat.com, inc. (TSXV: KSI) (“kneat.com“, “Kneat“, or the “Company“) is pleased to announce that a large multi-national pharmaceutical company has deployed the Kneat Gx platform to replace many of its paper-based validation and GxP testing processes within their highly regulated manufacturing facilities world wide. The Kneat Gx platform provides a compliant e-validation solution that enables life science companies to become efficient and compliant with an automated process that has traditionally been manual, in-efficient and paper-based. Our customer is reporting significant productivity and cycle time improvements; all supporting a faster time to market goal. This initial contract is for a period of three years and is valued at a minimum of $1.1 million CAD. Kneat Gx is a platform software product with robust inbuilt e-signature capability that meets the strict pharmaceutical industry requirements. It has been designed to allow the customer to configure, manage and modify their processes without coding knowledge. It is especially relevant to highly regulated processes, where the ability to standardise best practices and to have real-time global visibility is highly valued; thereby increasing compliance, driving efficiency and speed to market. Key features of Kneat Gx are its ease of deployment and usability. “We are delighted that this customer has chosen our software and is experiencing compelling benefits across their global network. We look forward to deepening our relationship by extending Kneat to more processes, enabling further innovation throughout their supply chain. We are proud to be a partner of this customer,” said Eddie Ryan, CEO of Kneat. ”Our customer is a global leader in the pharmaceutical industry and it gives us great pleasure that our software is supporting their business in such an important role.”

About Kneat

Kneat develops and markets the leading edge Kneat Gx software platform. Kneat Gx is an e-validation tool which enables the life sciences industry to become fully electronic with their many validation and testing processes. Our customers are reporting productivity increases in excess of 100%, cycle time reductions of up to 60% and a higher repeatable compliance standard. A key feature of the tool is that it does not restrict the user to a specific process, rather the user can quickly configure their process in the system. Our customers are streamlining and automating all validations (process, equipment, computer, cleaning and laboratory), commissioning and qualification, product changeovers, automation lifecycle management, vendor and project turnover management and more. For more information, please visit http://www.kneat.com/.

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the relationship between Kneat and the customer, the use of Kneat within the customer’s manufacturing process, the ability to scale the use of Kneat within the customer and the compliance of the Kneat Gx platform under regulatory audit and inspection. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investors’ own risk.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE kneat.com For further information: Sarah Oliver, CFO, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: inquiry@kneat.com

Kneat Announces Appointment of European Sales Director
HALIFAX, Nov. 3, 2016 /CNW/ – kneat.com, inc. (TSXV: KSI) (“kneat.com“, “Kneat” or the “Company“) is pleased to announce the appointment of Mr. Mark Geldard as its European Sales Director. Mr. Geldard will lead the Company’s sales and marketing activities throughout Europe. With over 23 years of experience in sales, marketing and business development within the software and IT services industry, Mr. Geldard is ideally suited for this position. Most recently he held the position of Senior Account Manager Life Sciences at NNIT A/S in Zurich, Switzerland. “Mark has a record of success and excellence, and combines extensive experience within both the software and life science industries,” said Eddie Ryan, CEO of Kneat. “We are pleased to welcome Mark to the team and look forward to working with him as we roll out our sales and marketing strategy in Europe.” “I’m excited to join Kneat as I see huge market potential for its software platform within the pharmaceutical industry in Europe,” said Mr. Geldard. “Kneat’s software provides an effective solution to the industry, and I am looking forward to working with clients who will benefit from this innovative product.”

About kneat.com

kneat.com develops and markets the leading edge Kneat Gx platform software that meets the stringent pharmaceutical industry regulatory requirements for all forms of validation, equipment changeover management, risk lifecycle management, change control and much more. It has been designed to allow the customer to configure and manage many regulated data and document processes in a paper-less environment.

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the ability to generate sales of the Kneat Gx platform, the ability to build relationships with current and prospective customers, the market potential for the Kneat Gx platform and the compliance of the Kneat Gx platform under regulatory audit and inspection. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor’s own risk.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE kneat.com For further information: Sarah Oliver, CFO, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: inquiry@kneat.com

Kneat.com Announces Completion of Arrangement and Merger
HALIFAX, June 27, 2016 – kneat.com, inc. (formerly, Fortune Bay Corp.) (TSX: FOR) (“kneat.com” or the “Company“) is pleased to announce the completion of the previously announced transaction (the “Transaction“), pursuant to which, among other things, the Company has: (i) spun-out its resource properties by way of a court-approved plan of arrangement in Ontario (the “Arrangement“); and (ii) acquired 100% of the issued and outstanding ordinary shares (the “Kneat Shares“) of Kneat Solutions Limited (“Kneat“) by way of a concurrent scheme of arrangement in Ireland (the “Merger“).

Pursuant to the Arrangement, the shareholders of the Company (the “Company Shareholders“) received one (1) new common share of kneat.com (each a “New Share“) and one and one half (1.5) of a common share (a “SpinCo Share“) of Fortune Bay Corp. (formerly, 9617337 Canada Limited), a newly formed exploration company (“SpinCo“), in exchange for each three (3) common shares of the Company held by them immediately prior to the effective time of the Arrangement and Merger, for a total issuance of 12,385,424 New Shares and 18,578,200 SpinCo Shares .

Pursuant to the Merger, the Company acquired 100% of the issued and outstanding Kneat Shares in consideration for issuance to the former holders of the Kneat Shares (the “Kneat Shareholders“) 27,178,260 New Shares, representing 68.7% of the issued and outstanding New Shares. Upon closing of the Transaction, the Company Shareholders hold 100% of the issued and outstanding SpinCo Shares and 31.3% of the issued and outstanding New Shares, with the former Kneat Shareholders holding the remaining 68.7% of the issued and outstanding New Shares.In addition to acquiring all the issued and outstanding Kneat Shares, kneat.com retained net CAD$8.2 million. SpinCo holds the Company’s interests in the Goldfields project in Saskatchewan and the Ixhuatán project and Huizopa net smelter royalty in Mexico. kneat.com owns and operates the existing business of Kneat.

In addition, in connection with the Arrangement, (i) the issued and outstanding stock options of the Company (the “Company Options“) were consolidated on a three for one basis (3:1), resulting in a total of 666,667 Company Options (“New Company Options“) at an average exercise price of $0.90; and (ii) the common share purchase warrants of the Company (the “Company Warrants“) were consolidated on a three for one basis (3:1) resulting in a total of 267,857 Company Warrants (“New Company Warrants“) at an exercise price of $0.90. Furthermore, consistent with the terms of the Arrangement, holders of the Company Warrants received one and one-half (1.5) common share purchase warrants (the “SpinCo Warrants“) for every one (1) Company Warrant held, exercisable at $0.60 per SpinCo Warrant, resulting in a total of 401,786 SpinCo Warrants.

Thus, as of today, kneat.com has 39,563,684 New Shares issued and outstanding. An additional 2,391,003 New Shares have been reserved for issuance in connection with the New Company Options and New Company Warrants issued to the former holders of Company Options and Company Warrants, pursuant to the Transaction.

In addition, as of today, SpinCo has 18,578,200 SpinCo Shares issued and outstanding. An additional 401,786 SpinCo Shares have been reserved for issuance in connection with the SpinCo Warrants issued to the former holders of Company Warrants, pursuant to the Transaction.

In connection with the Transaction, the Company changed its name from “Fortune Bay Corp.” to “kneat.com, inc.” and SpinCo changed its name from “9617337 Canada Limited” to “Fortune Bay Corp”.

The Ontario Superior Court of Justice (Commercial List) issued a final order approving the Arrangement on June 17, 2016 and the Arrangement became effective at the effective time, being 12:01 a.m. on June 21, 2016. The High Court of Ireland issued a final order approving the Merger on June 24, 2016 and the Merger became effective at the effective time, being 12:01 a.m. on June 27, 2016.

Subject to the receipt of final approval of the TSX Venture Exchange (the “TSXV“), the New Shares and the SpinCo Shares are expected to commence trading on the TSXV under the trading symbol “KSI” and “FOR” respectively, at the commencement of trading on July 5, 2016. The current Fortune Bay Corp. is expected to be delisted from the Toronto Stock Exchange on July 4, 2016.

kneat.com’s management team consists of the following persons at the following offices: Edmund Ryan – President and Chief Executive Officer; Kevin Fitzgerald – Executive Director of Research & Development; Brian Ahearne – Director of Quality; Sarah Oliver – Chief Financial Officer and Corporate Secretary.

The board of directors of kneat.com consists of the following individuals: Edmund Ryan, Kevin Fitzgerald, Paul Breen, James Osborne, Ian Ainsworth and Wade Dawe.

SpinCo’s management team consists of the following persons at the following offices: Wade Dawe – Chief Executive Officer and Sarah Oliver – Chief Financial Officer and Corporate Secretary.

The board of directors of SpinCo consists of the following individuals: Wade Dawe, Derrick Gill and Michael Gross.

For details of the Transaction, please see the Company’s management information circular dated May 13, 2016, which has been filed under the Company’s profile on SEDAR at www.sedar.com.

About Kneat.com, inc.

Kneat, headquartered in Limerick, Ireland, is in the business of developing and marketing the Kneat Gx platform software that meets the stringent pharmaceutical industry regulatory requirements for all forms of validation, equipment changeover management, risk lifecycle management, change control and much more. It has been designed to allow the customer to configure and manage many regulated data and document processes in a paper-less environment.

About Fortune Bay Corp.

Fortune Bay is engaged in the exploration and potential development of two primary mining projects: the Goldfields project and the Ixhuatán project. The Goldfields project is a property located in northern Saskatchewan and consists of two gold deposits: the Box deposit and the Athona deposit. The Ixhuatán project is located in the northern Chiapas State in Mexico.

Cautionary and Forward-Looking Statement

Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the final approval of the Transaction by the TSXV and the listing of SpinCo Shares and the New Shares on the TSXV. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at investors’ own risk.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information: inquiry@kneat.com

Management Information Circular

Management Information Circular – May 18, 2017


Financial Information

June 30, 2017 interim financial statements

June 30, 2017 MD&A

March 31, 2017 interim financial statements

March 31,2017 MD&A

December 31, 2016 annual financial statements

December 31, 2016 MD&A

September 30,2016 interim financial statements

September 30,2016 MD&A

June 30,2016 interim financial statements

June 30,2016 MD&A


Please refer to sedar.com for additional news and investor information


Corporate Policies

Whistleblower Policy

Code of Conduct

 

For investor relations inquiries, please contact Sarah Oliver at sarah.oliver@kneat.com